Filing Flows › Industrials › VitaNova Life Sciences (VNOV)
VitaNova Life Sciences (VNOV) earnings and revenue breakdown
Latest: Q1 FY27 · 10-Q filed Sep 14, 2026 · VitaNova Life Sciences (VNOV) Q1 FY27 earnings results →
Q1 FY27 Revenue up 210% year over year to $322K · 38¢ of every $1 of revenue lost · operating margin -38.0%
VitaNova Life Sciences made $322K in Q1 FY27 (+210% Y/Y): Sale of Food Products $235K, Dietary Supplement Products $87K. Operating margin -38.0%, net loss $123K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $322K in Q1 FY27, up 210% year over year and down 82% from the previous quarter. Sale of Food Products was the largest line at 73% of revenue. Dietary Supplement Products declined 13%.
Gross margin was 9.5%, down 56.7 points from Q1 FY26. Operating costs exceeded revenue by $122K, an operating margin of -38.0%. Operating expenses grew 51% against revenue growth of 210%. The fastest-growing cost line was General & admin (+73%). The quarter ended with a net loss of $123K, after a profit of $18K the previous quarter.
Operating cash flow was $7K (down 97% year over year). Working capital and other items added $130K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 FY27 | 10-Q | Sep 14, 2026 | $322K | +210% | -38.0% | −$123K | $7K |
| Q4 FY26 | 10-K | Jul 29, 2026 | $1.8M | -9% | -6.2% | $18K | $428K |
| Q3 FY26 | 10-Q | Mar 16, 2026 | $710K | +130% | 6.6% | −$44K | −$90K |
| Q2 FY26 | 10-Q | Dec 15, 2025 | $427K | +46% | 23.2% | $36K | $213K |
| Q1 FY26 | 10-Q | Sep 12, 2025 | $104K | -4% | -31.2% | −$46K | $264K |
| Q4 FY25 | 10-K | Jul 24, 2025 | $2.0M | +259% | 55.4% | $800K | $479K |
| Q3 FY25 | 10-Q | Mar 17, 2025 | $308K | 12× | 35.3% | $73K | $209K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About VitaNova Life Sciences
We are a U.S. focused consumer health, beauty and lifestyle company that develops, acquires, markets and sells branded nutritional supplements, functional beverages and complementary lifestyle products. Our dietary supplement operations are consolidated and commercialized through NutriPeak Trading Corporation (“NTC”), a wholly owned subsidiary formed in November 2023. NTC was established with the purpose of marketing and supplying dietary supplement products. Since November 2023, substantially all of the Company’s operations have been conducted through NTC. NTC is organized to develop a two tier portfolio of products: an advanced, science-oriented line intended to support general cellular and cognitive wellness and a mass market line optimized for high velocity e-commerce and marketplace channels.
In its own words, from its 10-K, filed Jul 29, 2026.
VitaNova Life Sciences against its Wholesale-Apparel, Piece Goods & Notions peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VNOV VitaNova Life Sciences | Q1 FY27 | $322K | +210% | -38.0% |
| WEYS Weyco Group | Q3 2026 | $77.0M | +5% | 17.8% |
Source: VitaNova Life Sciences 10-Q on SEC EDGAR · CIK 1699709 · Wholesale-Apparel, Piece Goods & Notions
More on VNOV
History
Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results